Author details

Full Name

Keith A Ching

Affiliation

ORCID

Career Start Year

1999

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37269335	SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.	Cancer Discov	2023
35488900	A phase 1b study of glasdegibâ¿¿+â¿¿azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.	Annals of Hematology	2022
36216827	Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.	Nature Communications	2022
34376502	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.	Cancer Immunology Research	2021
33901870	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.	ESMO Open	2021
34893775	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.	Nat Med	2021
33268821	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.	Nat Commun	2020
32144134	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 Non-Hodgkin Lymphomas.	Clinical Cancer Research	2020
32049022	Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling.	Cell Rep	2020
32900860	FcÎ³RIIB engagement drives agonistic activity of Fc-engineered Î±OX40 antibody to stimulate human tumor-infiltrating T cells.	Journal for ImmunoTherapy of Cancer	2020
32895571	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.	Nat Med	2020
25564152	PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a Î³-secretase inhibitor.	Clin Cancer Res	2015
25592564	Cell Index Database (CELLX): a web tool for cancer precision medicine.	Pac Symp Biocomput	2015
24462510	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma.	Genomics	2014
23610116	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.	Journal of Clinical Oncology	2013
24107449	Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).	Mol Cancer Ther	2013
22222631	An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.	Mol Cancer Ther	2012
22745804	A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.	PLoS One	2012
22135232	Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.	Molecular Cancer Therapeutics	2012
21876557	Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency.	Cell Res	2011
19295514	Histone modifications at human enhancers reflect global cell-type-specific gene expression.	Nature	2009
18258921	Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets.	Genome Res	2008
17382889	Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome.	Cell	2007
17277777	Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.	Nat Genet	2007
17255266	An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.	Clin Cancer Res	2007
16596450	Data and animal management software for large-scale phenotype screening.	Mamm Genome	2006
16802597	Inducible T cell tyrosine kinase (ITK): structural requirements and actin polymerization.	Advances in Experimental Medicine and Biology	2006
16103083	Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.	Cancer Research	2005
15075390	A gene atlas of the mouse and human protein-encoding transcriptomes.	Proc Natl Acad Sci U S A	2004
12857950	Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates.	Proceedings of the National Academy of Sciences of the United States of America	2003
11904358	Large-scale analysis of the human and mouse transcriptomes.	Proc Natl Acad Sci U S A	2002
11286686	Itk/Emt: a link between T cell antigen receptor-mediated Ca2+ events and cytoskeletal reorganization.	Trends in Immunology	2001
11534548	A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes.	Cell	2001
11123316	Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain.	Journal of Immunology	2001
10861059	TCR/CD3-Induced activation and binding of Emt/Itk to linker of activated T cell complexes: requirement for the Src homology 2 domain.	Journal of Immunology	2000
10730270	Activation of heterotrimeric GTP-binding proteins upon TCR/CD3 engagement.	Methods in Molecular Biology	2000
10570288	Emt/Itk associates with activated TCR complexes: role of the pleckstrin homology domain.	Journal of Immunology	1999